<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-11-18546</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0031196</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Anatomy and physiology</subject>
            <subj-group>
              <subject>Endocrine system</subject>
              <subj-group>
                <subject>Endocrine physiology</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Proteins</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Biotechnology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Chemical biology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Anatomy and physiology</subject>
            <subj-group>
              <subject>Endocrine system</subject>
              <subj-group>
                <subject>Endocrine physiology</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Oncology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Chemistry</subject>
          <subject>Physiology</subject>
          <subject>Biotechnology</subject>
          <subject>Oncology</subject>
          <subject>Biochemistry</subject>
        </subj-group>
      </article-categories><title-group><article-title>Probing High Affinity Sequences of DNA Aptamer against VEGF<sub>165</sub></article-title><alt-title alt-title-type="running-head">Probing High Affinity Sequences of VEGF<sub>165</sub> Aptamer</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Harleen</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yung</surname>
            <given-names>Lin-Yue Lanry</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">          <addr-line>Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, Singapore</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Addison</surname>
            <given-names>Christina Lynn</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Ottawa Hospital Research Institute, Canada</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">cheyly@nus.edu.sg</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: HK LY. Performed the experiments: HK. Analyzed the data: HK LY. Contributed reagents/materials/analysis tools: HK LY. Wrote the paper: HK LY.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2012</year>
      </pub-date><pub-date pub-type="epub">
        <day>16</day>
        <month>2</month>
        <year>2012</year>
      </pub-date><volume>7</volume><issue>2</issue><elocation-id>e31196</elocation-id><history>
        <date date-type="received">
          <day>21</day>
          <month>9</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>1</month>
          <year>2012</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2012</copyright-year><copyright-holder>Kaur, Yung</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Vascular endothelial growth factor (VEGF<sub>165</sub>) is a potent angiogenic mitogen commonly overexpressed in cancerous cells. It contains two main binding domains, the receptor-binding domain (RBD) and the heparin-binding domain (HBD). This study attempted to identify the specific sequences of the VEa5 DNA aptamer that exhibit high binding affinity towards the VEGF<sub>165</sub> protein by truncating the original VEa5 aptamer into different segments. Using surface plasmon resonance (SPR) spectroscopy for binding affinity analysis, one of the truncated aptamers showed a &gt;200-fold increase in the binding affinity for HBD. This truncated aptamer also exhibited high specificity to HBD with negligible binding affinity for VEGF<sub>121</sub>, an isoform of VEGF lacking HBD. Exposing colorectal cancer cells to the truncated aptamer sequence further confirmed the binding affinity and specificity of the aptamer to the target VEGF<sub>165</sub> protein. Hence, our approach of aptamer truncation can potentially be useful in identifying high affinity aptamer sequences for the biological molecules and targeting them as antagonist for cancer cell detection.</p>
      </abstract><funding-group><funding-statement>This work was supported by research funding from the Singapore Ministry of Education Academic Research Fund Tier 2 grant MOE2008-T2-1-046 and Tier 1 grant R279000282112. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="9"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Short single stranded nucleic acids referred to as aptamers are widely being explored as molecules of high affinity and specificity for binding a diverse array of target molecules ranging from high molecular weight proteins to small ions and nucleotides <xref ref-type="bibr" rid="pone.0031196-Bock1">[1]</xref>–<xref ref-type="bibr" rid="pone.0031196-Davis1">[3]</xref>. Aptamers contain functional moieties that fold into different secondary conformations, such as hairpin stem and loops, G-quadruplexes, bulges and pseudoknots, and they exhibit substantial impact on the conformational stability and target binding affinity of the aptamer. The non-immunogenic property of aptamer provides additional advantage over the prevalent antibodies and makes them a promising candidate for therapeutic and diagnostic application <xref ref-type="bibr" rid="pone.0031196-Jayasena1">[4]</xref>. “Macugen” is the first FDA-approved aptamer-based therapeutic for treating the wet-form of age-related macular degeneration. The successful approval of this 27-mer RNA aptamer as therapeutic drug in 2004 has demonstrated the potential of aptamers as future therapeutics <xref ref-type="bibr" rid="pone.0031196-Ruckman1">[5]</xref>. Currently, 8 aptamers are in various phases of clinical trials for treating different diseases <xref ref-type="bibr" rid="pone.0031196-Sayyed1">[6]</xref>–<xref ref-type="bibr" rid="pone.0031196-Green1">[13]</xref>. These include NOX-E36 L-RNA aptamer against CCL2 ligand in Type 2 diabetes, G-quadruplex forming AS1411 DNA aptamer against nucleolin in acute myeloid leukemia, and phosphorothioate-modified ARC1779 DNA aptamer against von Willebrand factor (vWF) in carotid artery disease <xref ref-type="bibr" rid="pone.0031196-Ninichuk1">[7]</xref>, <xref ref-type="bibr" rid="pone.0031196-Bates1">[8]</xref>, <xref ref-type="bibr" rid="pone.0031196-Diener1">[10]</xref>.</p>
      <p>Aptamers are commonly screened and obtained by <italic>in vitro</italic> selection technique, also termed as systematic evolution of ligands by exponential enrichment (SELEX). SELEX starts with a random pool of oligonucleotide library incubated with the target molecule and involves continuous rounds of affinity and amplification steps to screen for the high affinity sequences <xref ref-type="bibr" rid="pone.0031196-Ellington1">[14]</xref>, <xref ref-type="bibr" rid="pone.0031196-Tuerk1">[15]</xref>. Different selection process has been used for isolation of high binding affinity aptamers in SELEX, such as nitrocellulose membrane filtration, surface plasmon resonance (SPR), capillary electrophoresis and bead-based methods <xref ref-type="bibr" rid="pone.0031196-Tuerk1">[15]</xref>–<xref ref-type="bibr" rid="pone.0031196-Tok1">[18]</xref>. Binding affinity and specificity are the crucial criteria for the therapeutic use of aptamers. Generally, not all nucleotide domains of the post-screened aptamer play an important role in target binding. The non-binding domain may actually interfere with the interaction between the aptamer and target protein by formation of complex secondary structures, and eventually prevents the binding domain to fold into the desired conformation for binding to the target <xref ref-type="bibr" rid="pone.0031196-Jayasena1">[4]</xref>. This may result in reduction or complete loss of the binding affinity as well as higher synthesis cost. Therefore, identifying the high binding affinity domains in the post-screened aptamer is a key step to perform for producing potent aptamers with higher affinity/specificity for various biomedical applications.</p>
      <p>Different strategies have been adopted to enhance the aptamer binding affinity for its target and to make them suitable for different biological applications. One of the commonly used strategies includes chemical modification of the aptamer structure at 5′- or 3′-terminus, nucleobase, sugar, and phosphate backbone. The modifications include (i) the addition of functional groups, such as amino (-NH<sub>2</sub>), fluoro (-F), <italic>O</italic>-methyl (-OCH<sub>3</sub>), locked nucleic acids (LNAs) or phosphorothioate linkages (PS-linkages) to make aptamers nuclease resistant, and (ii) conjugation with high molecular weight polyethylene glycol (PEG) to enhance <italic>in vivo</italic> circulating half-life <xref ref-type="bibr" rid="pone.0031196-Ruckman1">[5]</xref>, <xref ref-type="bibr" rid="pone.0031196-Jellinek1">[19]</xref>–<xref ref-type="bibr" rid="pone.0031196-Boomer1">[26]</xref>. Apart from improving the stability of the aptamer, these modifications can improve the affinity of the aptamer in the cellular environment. Additionally, software algorithms have been used to deduce the binding domains by comparing different sequences as well as to predict the secondary structure <xref ref-type="bibr" rid="pone.0031196-Kato1">[27]</xref>, <xref ref-type="bibr" rid="pone.0031196-Shangguan1">[28]</xref>. Strategies such as partial fragmentation, enzymatic footprinting, and recently microarray based binding sequence determination have also been employed for probing the high affinity binding sequences <xref ref-type="bibr" rid="pone.0031196-Green1">[13]</xref>, <xref ref-type="bibr" rid="pone.0031196-Sayer1">[29]</xref>, <xref ref-type="bibr" rid="pone.0031196-Katilius1">[30]</xref>.</p>
      <p>Vascular endothelial growth factor (VEGF) is a mitogenic protein secreted by both endothelial and tumor cells and induces physiological and pathological angiogenesis inside the body. Through alternate exon splicing of single human VEGF gene, several isoforms of this growth factor, including VEGF<sub>165</sub>, VEGF<sub>121</sub>, VEGF<sub>189</sub> and VEGF<sub>206</sub>, are generated <xref ref-type="bibr" rid="pone.0031196-Houck1">[31]</xref>. Of these, VEGF<sub>165</sub> and VEGF<sub>121</sub> are the predominant isoforms. VEGF<sub>165</sub>, which contains both heparin-binding domain (HBD) and receptor-binding domain (RBD), has been shown to be a more potent mitogen in inducing angiogenesis compared with VEGF<sub>121</sub>, which contains only RBD <xref ref-type="bibr" rid="pone.0031196-Park1">[32]</xref>–<xref ref-type="bibr" rid="pone.0031196-Keyt1">[34]</xref>.</p>
      <p>A previous work by Ikebukuro and co-workers has identified a 66mer DNA aptamer (VEa5) that binds to HBD of VEGF<sub>165</sub> protein with K<sub>d</sub> value of 130 nM <xref ref-type="bibr" rid="pone.0031196-Hasegawa1">[35]</xref>. Since increasing the binding affinity of this aptamer is important for further therapeutic development, they later adopted the dimerization method to reduce the K<sub>d</sub> of VEa5 aptamer to 6 nM, which is 20 times better than the original monomeric VEa5 <xref ref-type="bibr" rid="pone.0031196-Hasegawa2">[36]</xref>. In the present study, we adopted a different strategy to improve the binding affinity of the VEa5 aptamer. We attempted to identify the high affinity binding sequences within the 66mer VEa5 by truncating its stem-loop regions and investigated the impact on the binding affinity against HBD of VEGF<sub>165</sub> protein using surface plasmon resonance (SPR) spectroscopy. Our results demonstrated that the truncation of the stem-loop regions can locate the key binding domain in the aptamer and the truncated sequence exhibits substantially higher binding affinity compared with the entire VEa5 aptamer. <italic>In vitro</italic> binding study with colorectal cancer cells overexpressed with VEGF protein further confirmed the high binding affinity of the truncated aptamer.</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Materials</title>
        <p>The HPLC purified oligonucleotides (both unlabeled and fluorescent-labeled) were purchased from Sigma-Aldrich. The recombinant human carrier free VEGF<sub>165</sub> (molecular weight of 38 kDa, pI = 8.25) and VEGF<sub>121</sub> (molecular weight of 28 kDa, pI = 6.4) proteins were purchased from R &amp; D systems. CM5 sensor chips were purchased from GE Healthcare for protein immobilization. 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and ethanolamine-HCl were purchased from Sigma-Aldrich. Sodium acetate (anhydrous) was purchased from Fluka. Human colorectal adenocarcinoma HT-29 cell line was a gift from Dr. Partha Roy's lab. Normal human fetal lung fibroblast MRC-5 cells were obtained from ATCC. Dulbecco's modified eagle's media (DMEM) media, RPMI-1640 and fetal bovine serum (FBS) was purchased from Caisson laboratories. Trypsin-EDTA and 1% penicillin/streptomycin mixture were purchased from PAN biotech. Phosphate buffer saline (PBS) buffer was purchased from 1<sup>st</sup> Base. Tween-20 was purchased from USB Corporation.</p>
      </sec>
      <sec id="s2b">
        <title>Binding affinity of truncated aptamers via surface plasmon resonance spectroscopy</title>
        <p>To elucidate the role of stem-loop regions of the VEa5 aptamer in VEGF binding, the original sequence of the VEa5 was truncated. The corresponding binding affinity of truncated aptamers was investigated using surface plasmon resonance (SPR) spectroscopy, where VEGF<sub>165</sub> and VEGF<sub>121</sub> acted as ligands and were directly immobilized on the sensor chip. Briefly, the carboxylic group on the sensor chip was activated by standard amine coupling procedure using freshly prepared EDC/NHS. VEGF<sub>165</sub> or VEGF<sub>121</sub> (25 µg/ml) in acetate buffer (pH 6.0) was then injected into the sensor chip at flow rate 8 µl/min to reach ∼200RU immobilization level. The deactivation was done by ethanolamine-HCl to block unreacted carboxyl groups. The binding analysis was carried out with truncated aptamers at different concentrations (0.2 to 100 nM) using a BIAcore 2000 instrument (GE Healthcare). The running condition was set at 30 µl/min flow rate, 25°C, 3 min association time and 5 min dissociation time. PBS and 0.005% tween-20 solution mixture was used as the running buffer, and 50 mM NaOH as the regeneration buffer. All the buffers were filtered and degassed prior to each experiment. Blank surfaces were used for background subtraction. Upon injection of the truncated aptamers, sensorgrams recording the association/dissociation behavior of the VEGF-aptamer complex were collected. By varying the truncated aptamer concentration, a series of sensorgrams (<xref ref-type="fig" rid="pone-0031196-g001">Figure 1</xref>) were obtained and subsequently analyzed using the 1∶1 Langmuir model provided in the BIAevaluation software (version 4.1) to calculate the equilibrium dissociation constant K<sub>d</sub>. All SPR measurements were performed in triplicates.</p>
        <fig id="pone-0031196-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Typical SPR sensorgrams demonstrating interaction of aptamer with immobilized VEGF<sub>165</sub> protein at different concentrations (bottom to top, 0.2 to 100 nM).</title>
            <p>Point A to B corresponds to the association phase and point B to C corresponds to the dissociation phase in all the sensorgrams. Shown here is the SL<sub>2</sub>-B aptamer (K<sub>d</sub> = 0.50±0.32 nM).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g001" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2c">
        <title>Cellular binding of truncated aptamer via flow cytometry analysis</title>
        <p>The HT-29 colorectal cancer and MRC-5 human fetal lung fibroblast cells were plated at a seeding density of 10<sup>5</sup> cells/ml in DMEM and RPMI-1640 media and were allowed to attach for 48 hours in humidified incubator containing 5% CO<sub>2</sub>, 1% O<sub>2</sub> and 94% N<sub>2</sub> (hypoxia) at 37°C. The hypoxia condition was maintained by culturing the cells in a sealed hypoxia chamber (Billups-Rothenberg). The cells were trypsinized for very short time and incubated with 5′-PE-texas red labeled truncated aptamer of different concentrations for 2 hours at 37°C in culture medium. The cells were then centrifuged for 5 min at 1500 rpm and re-suspended in PBS buffer for flow cytometry analysis immediately. Analysis was performed on a Beckman-Coulter CyAn ADP flow cytometer using 488 nm excitation and 613/20 nm emission filter. 20,000 events were collected for each sample. All the experiments for binding assay were repeated at least 3 times. Relative fluorescence was determined using SUMMIT V 4.3.02 software. For calculation of equilibrium dissociation (K<sub>d</sub>), the fluorescence intensity signal was plotted against fluorescently labeled aptamer concentration by fitting in equation Y = B<sub>max</sub> X/(K<sub>d</sub>+X) using SigmaPlot software. Sequence specificity of the SL<sub>2</sub>-B aptamer was determined using a scrambled sequence. The K<sub>d</sub> value of the SL<sub>2</sub>-B aptamer was calculated by subtracting the fluorescence intensity signal from the scrambled sequence.</p>
        <p>Competitive aptamer binding assay was performed to determine the effect of unlabeled SL<sub>2</sub>-B aptamer on the binding capability of 5′-PE-texas red labeled truncated aptamer. HT-29 colorectal cancer cells were incubated with 20-fold excess concentration of unlabeled aptamer as competitor (10 nM) simultaneously with 5′-PE-texas red labeled aptamer (0.5 nM). All other experimental conditions and procedures were same as described for the flow cytometry analysis.</p>
      </sec>
      <sec id="s2d">
        <title>Fluorescence microscopy imaging</title>
        <p>The HT-29 cells and MRC-5 cells were seeded in 24-well plate in DMEM and RPMI-1640 media respectively. Cells were plated at a seeding density of 10<sup>5</sup>cells/ml in their individual media supplemented with FBS and penicillin/streptomycin mixture in the same hypoxic conditions as mentioned above. Subsequently, the cells were incubated with 5′-PE-texas red labeled truncated aptamer at 37°C for 2 hours and washed with PBS (pH = 7.4) three times to remove unbound aptamer. Sequence specificity of the truncated aptamer was determined using a scrambled sequence as control. Images of aptamer binding to cells were acquired using a Leica DMIL fluorescence microscope.</p>
      </sec>
      <sec id="s2e">
        <title>Statistical analysis</title>
        <p>Results from at least 3 independent experiments in flow cytometry experiment were analyzed using Student's t-test. p-value&lt;0.05 was considered significant. Data are expressed as mean ± S.D.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results and Discussion</title>
      <sec id="s3a">
        <title>Binding analysis of aptamer-VEGF complex by surface plasmon resonance (SPR)</title>
        <p>The induction of the aptamer folding was done using predictions by the mfold software <xref ref-type="bibr" rid="pone.0031196-Zuker1">[37]</xref>. As shown in <xref ref-type="fig" rid="pone-0031196-g002">Figure 2</xref>, VEa5 displays complex hairpin stem-loop secondary structure with three stem-loop regions and several unpaired terminal nucleotides. Based on the SPR measurement, the original VEa5 aptamer exhibited a binding constant of K<sub>d</sub> = 120 nM to the surface immobilized VEGF<sub>165</sub> (<xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>). This value is very close to the K<sub>d</sub> value of the VEa5 aptamer binding to the heparin-binding domain (HBD) of VEGF<sub>165</sub> reported in the literature (K<sub>d</sub> = 130 nM) <xref ref-type="bibr" rid="pone.0031196-Hasegawa1">[35]</xref>.</p>
        <fig id="pone-0031196-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Schematic representation of the secondary structure of original VEa5 aptamer as predicted by the mfold program.</title>
            <p>Nucleotide 4–20 forms the stem-loop 1 (SL<sub>1</sub>) region, nucleotide 22–38 forms the stem-loop 2 (SL<sub>2</sub>) region, and nucleotide 43–50 forms stem-loop 3 (SL<sub>3</sub>) region. Nucleotide 28–33 forms internal loop 1 (IL<sub>1</sub>), and nucleotide 24–27+34–36 together forms internal loop 2 (IL<sub>2</sub>) within SL<sub>2</sub> region.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g002" xlink:type="simple"/>
        </fig>
        <table-wrap id="pone-0031196-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0031196.t001</object-id><label>Table 1</label><caption>
            <title>Different aptamer sequences along with their equilibrium dissociation constant (K<sub>d</sub>) values determined using surface plasmon resonance (SPR) spectroscopy.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0031196-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Sequences of original and various truncated aptamers (5′------ 3′)<xref ref-type="table-fn" rid="nt101">*</xref></td>
                <td align="left" colspan="1" rowspan="1">K<sub>d</sub></td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>VEa5 <named-content content-type="gene" xlink:type="simple"><monospace><underline><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA</named-content></underline></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">120±1.8 nM</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SL<sub>12</sub> <named-content content-type="gene" xlink:type="simple"><monospace><underline><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGG</named-content></underline><named-content content-type="gene" xlink:type="simple">TGTGCTGGCCAGATAGTATGTGCAATCA</named-content></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">5±0.45 nM</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SL<sub>1</sub> <named-content content-type="gene" xlink:type="simple"><monospace><underline><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATTCAATTGG</named-content></underline><named-content content-type="gene" xlink:type="simple">GCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA</named-content></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">No Binding</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SL<sub>2</sub> <named-content content-type="gene" xlink:type="simple"><monospace><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATTCAATTGGG<underline>CCCGTCCGTATGGTGGG</underline>TGTGCTGGCCAGATAGTATGTGCAATCA</named-content></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">49±2.4 nM</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SL<sub>2</sub>-A <named-content content-type="gene" xlink:type="simple"><monospace><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATTCAATTGG<underline>GCCCGTCCGTATGGTGGGT</underline>GTGCTGGCCAGATAGTATGTGCAATCA</named-content></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">10±1.1 nM</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SL<sub>2</sub>-B <named-content content-type="gene" xlink:type="simple"><monospace><named-content content-type="gene" xlink:type="simple">ATACCAGTCTATT<underline>CAATTGGGCCCGTCCGTATGGTGGGT</underline>GTGCTGGCCAGATAGTATGTGCAATCA</named-content></monospace></named-content></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">0.5±0.32 nM</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>*The underlined and bold section indicates the aptamer sequence and the non-bold grey section indicates the truncated sequence. In aptamer sequence terminology, the subscript number indicates the presence of the particular stem-loop region.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>To better understand the significance of stem-loop (SL) regions towards binding affinity, we conducted a few truncations on the SL regions. By truncating SL<sub>3</sub> at the 3′ end together with 3′-termini hanging nucleotides and the nucleotides between SL<sub>2</sub> and SL<sub>3</sub>, we obtained SL<sub>12</sub> (<xref ref-type="fig" rid="pone-0031196-g003">Figure 3A</xref> and <xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>) and it exhibited a K<sub>d</sub> value of 5 nM, a striking 24-fold increase in the binding affinity compared with the original VEa5 aptamer. Further truncation of SL<sub>2</sub> to yield SL<sub>1</sub> (<xref ref-type="fig" rid="pone-0031196-g003">Figure 3B</xref> and <xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>), however, resulted in complete loss of binding activity towards VEGF<sub>165</sub>. These two modifications pointed to the indispensable role of SL<sub>2</sub> in the binding process. The increase in the binding affinity could be due to the deletion of non-binding nucleotides that hampers the binding process and hence, their removal may lead to more desired secondary conformation in the truncated aptamer required for binding to the HBD of VEGF<sub>165</sub> protein <xref ref-type="bibr" rid="pone.0031196-Shangguan1">[28]</xref>.</p>
        <fig id="pone-0031196-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Schematic representation of the secondary structures of various truncated aptamers as predicted by the mfold program.</title>
            <p>(A) SL<sub>12</sub> indicates the presence of SL<sub>1</sub> and SL<sub>2</sub> regions together, (B) SL<sub>1</sub> indicates the presence of SL<sub>1</sub> region only and (C) SL<sub>2</sub> indicates the presence of SL<sub>2</sub> region only. (D) SL<sub>2</sub>-A and (E) SL<sub>2</sub>-B correspond to secondary structures formed after addition of nucleotides to SL<sub>2</sub> region.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g003" xlink:type="simple"/>
        </fig>
        <p>We next truncated SL<sub>1</sub> and left with only the SL<sub>2</sub> sequence for VEGF<sub>165</sub> binding analysis, and surprisingly we obtained lower binding affinity. With K<sub>d</sub> value of 49 nM (<xref ref-type="fig" rid="pone-0031196-g003">Figure 3C</xref> and <xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>), the binding affinity of the SL<sub>2</sub> sequence was approximately 10 times higher than the K<sub>d</sub> of SL<sub>12</sub>. This prompted us to further investigate the role of the additional sequence next to the 3′ and 5′ ends of the SL<sub>2</sub> region. By adding a single nucleotide at both 5′ and 3′-ends of the SL<sub>2</sub> aptamer (SL<sub>2</sub>-A, <xref ref-type="fig" rid="pone-0031196-g003">Figure 3D</xref>), we were able to lower the K<sub>d</sub> value by almost 5-fold (K<sub>d</sub> = 10 nM, <xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>) compared to the SL<sub>2</sub> aptamer. Further addition of nucleotides to 3′-end did not yield any improvement in the binding affinity. However, adding another 7 nucleotides at 5′-end of the SL<sub>2</sub> aptamer (SL<sub>2</sub>-B, <xref ref-type="fig" rid="pone-0031196-g003">Figure 3E</xref>) showed further enhancement in the binding affinity (K<sub>d</sub> = 0.5 nM, <xref ref-type="table" rid="pone-0031196-t001">Table 1</xref>), and this represented a 90-fold increase compared with the SL<sub>2</sub> aptamer, and more than 200-fold increase compared with the original VEa5 aptamer and 10-fold increase compared with the dimerized VEa5 aptamer <xref ref-type="bibr" rid="pone.0031196-Hasegawa2">[36]</xref>. A possible explanation is that the addition of nucleotides to the 5′-end provides more conformational stability to the aptamer which helps in improving the binding competence of the SL<sub>2</sub>-B sequence <xref ref-type="bibr" rid="pone.0031196-Potty1">[38]</xref>. We also attempted to truncate the internal loops of SL<sub>2</sub> (IL<sub>1</sub> and IL<sub>2</sub>, <xref ref-type="fig" rid="pone-0031196-g002">Figure 2</xref>) but the removal of either loops reduced the binding affinity. Therefore, SL<sub>2</sub>-B is thought to be the minimal sequence required in VEa5 aptamer to provide high binding affinity to HBD of VEGF<sub>165</sub>.</p>
        <p>To address the selectivity of the truncated SL<sub>2</sub>-B aptamer to VEGF<sub>165</sub> binding, VEGF<sub>121</sub> was selected for the binding comparison. VEGF<sub>121</sub> is another spliced form of VEGF mRNA that constitutes only the receptor-binding domain (RBD) but is devoid of HBD. HBD assists in the binding of VEGF protein to the heparin sulfate (HS) and heparin sulfate proteoglycans (HSPGs) present on the extracellular matrix of the cell membrane <xref ref-type="bibr" rid="pone.0031196-Park1">[32]</xref>. This enhances the interaction of VEGF with its receptors (VEGFR-1/Flt-1 and VEGFR-2/KDR) and the specific co-receptor neuropilins, triggering the cellular angiogenic response in malignant cells <xref ref-type="bibr" rid="pone.0031196-Keyt1">[34]</xref>.</p>
        <p>Compared with VEGF<sub>165</sub>, the binding of VEGF<sub>121</sub> to the membrane receptors is not strong, making it not potent to generate intense angiogenic signal. Using SL<sub>2</sub>-B for binding analysis with VEGF<sub>121</sub> under same buffer condition (<xref ref-type="fig" rid="pone-0031196-g004">Figure 4</xref>), substantial reduction in the response signal and minimal binding (K<sub>d</sub> = 10.2 µM) was observed compared to VEGF<sub>165</sub>. This confirms the binding selectivity of the truncated SL<sub>2</sub>-B aptamer on HBD of the VEGF<sub>165</sub> protein.</p>
        <fig id="pone-0031196-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Sensorgrams demonstrating interaction of SL<sub>2</sub>-B aptamer with immobilized VEGF<sub>165</sub> and VEGF<sub>121</sub> proteins using SPR spectroscopy.</title>
            <p>Point A to B corresponds to the association phase and point B to C corresponds to the dissociation phase in the sensorgrams. Shown here is SL<sub>2</sub>-B aptamer binding with VEGF<sub>165</sub> protein (K<sub>d</sub> = 0.50±0.32 nM) and VEGF<sub>121</sub> protein (K<sub>d</sub> = 10.2±1.89 µM).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g004" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3b">
        <title><italic>In vitro</italic> cellular binding analysis of SL<sub>2</sub>-B aptamer-VEGF complex</title>
        <p>Compared to techniques such as nitrocellulose membrane filtration or capillary electrophoresis, cell-based technique, such as flow cytometry, isolates aptamer sequences that have the ability to bind to their target with high affinity and specificity in a more physiologically relevant environment <xref ref-type="bibr" rid="pone.0031196-Davis2">[39]</xref>, <xref ref-type="bibr" rid="pone.0031196-Daniels1">[40]</xref>. Thus, it has been considered as a more direct strategy for studying the binding of aptamers to their targets on cellular surface.</p>
        <p>To validate the increase in the binding affinity of the truncated SL<sub>2</sub>-B aptamer and to determine its target specificity at cellular level, we exposed the fluorescent-labeled SL<sub>2</sub>-B sequence directly on the HT-29 colorectal cancer cells and normal MRC-5 fibroblast cells (control) under 1% O<sub>2</sub> hypoxia condition by flow cytometry analysis. As shown in <xref ref-type="fig" rid="pone-0031196-g005">Figure 5A</xref>, a significant peak shift (increase in the fluorescent signal) was observed for SL<sub>2</sub>-B aptamer at different concentrations, compared to control sample (only cells) in response to hypoxia conditions in HT-29 cells (p-value&lt;0.001). The percentage of fluorescent-labeled cells increased with the increase in the concentration of the SL<sub>2</sub>-B aptamer, indicating the binding of the SL<sub>2</sub>-B aptamer to the cell surface. In contrast, when using normal MRC-5 fibroblast cells, no enhancement in the fluorescent signal was observed after treatment with different SL<sub>2</sub>-B aptamer concentrations (<xref ref-type="fig" rid="pone-0031196-g005">Figure 5B</xref>, not significant (n.s.) compared to negative control). Since the VEGF protein is overexpressed in HT-29 cells but not the normal MRC-5 cells, the result showed that SL<sub>2</sub>-B can specifically form aptamer-VEGF complex on the HT-29 cell membrane. The K<sub>d</sub> value of the SL<sub>2</sub>-B towards VEGF was further evaluated using flow cytometry data (<xref ref-type="fig" rid="pone-0031196-g006">Figure 6</xref>). The K<sub>d</sub> value for the SL<sub>2</sub>-B aptamer to the cell surface was found to be 1.0 nM, which is close to the K<sub>d</sub> value determined by SPR technique (<xref ref-type="fig" rid="pone-0031196-g006">Figure 6</xref>). Repeating the same experiment at normoxia condition (i.e. 21% O<sub>2</sub>) did not yield any observable binding of SL<sub>2</sub>-B aptamer to the cells. The result is in agreement with the fact that the hypoxia condition enhances production of VEGF protein in HT-29 cells <xref ref-type="bibr" rid="pone.0031196-Waleh1">[41]</xref>–<xref ref-type="bibr" rid="pone.0031196-Calvani1">[43]</xref>.</p>
        <fig id="pone-0031196-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Representative flow cytometry profiles and quantitative analysis of flow cytometry results in (A) HT-29 cells and (B) MRC-5 cells after SL<sub>2</sub>-B aptamer at different concentrations (red – 0 nM (negative control), green – 0.5 nM, pink – 10 nM, blue – 100 nM), **Significant difference compared with the negative control (p-value&lt;0.001), n.s. – not significant.</title>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g005" xlink:type="simple"/>
        </fig>
        <fig id="pone-0031196-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Binding curve of SL<sub>2</sub>-B aptamer with HT-29 cells.</title>
            <p>Cells were incubated with different SL<sub>2</sub>-B aptamer concentrations ranging from 0 to 100 nM. The fluorescence intensity originating from the scrambled sequence at each concentration was subtracted from the fluorescence intensity of corresponding SL<sub>2</sub>-B aptamer. The actual fluorescence intensity was fitted into SigmaPlot software to determine the K<sub>d</sub>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g006" xlink:type="simple"/>
        </fig>
        <p>Hypoxia is one of the crucial physiological factors that exert profound impact on the metabolism, invasion and tumor progression, thereby affecting many oncogenic pathways. Inadequate level of cellular oxygen leads to aggressive phenotypic changes in the tumor cells, and is primarily responsible for their resistance against the therapies and poor prognosis <xref ref-type="bibr" rid="pone.0031196-Vaupel1">[44]</xref>. Exposure to hypoxia milieu upregulates the expression of master regulator Hypoxia-Inducible Factor 1 gene (HIF-1 gene) in the solid tumors, which switch on the transcription of several downstream genes, in particular, VEGF <xref ref-type="bibr" rid="pone.0031196-Minchenko1">[45]</xref>. The expression of VEGF protein and its two tyrosine kinase receptors – VEGFR-1/Flt-1 and VEGFR-2/KDR is induced by the transcription and stabilization of VEGF mRNA in response to hypoxia, resulting in increase rate of vascularization in tumor <xref ref-type="bibr" rid="pone.0031196-Neufeld1">[46]</xref>–<xref ref-type="bibr" rid="pone.0031196-Shima1">[48]</xref>.</p>
        <p>The binding ability of SL<sub>2</sub>-B aptamer for VEGF protein in HT-29 cells was evaluated by competing 5′-PE-texas red labeled SL<sub>2</sub>-B sequence against the unlabeled SL<sub>2</sub>-B sequence. As shown in <xref ref-type="fig" rid="pone-0031196-g007">Figure 7</xref>, the presence of 20-fold excess of unlabeled aptamer significantly decreased the fluorescent signal from the PE-texas red labeled aptamer (p-value&lt;0.05). This result suggests that both the labeled and unlabeled SL<sub>2</sub>-B aptamer binds to the same target, the VEGF protein on HT-29 cell membrane.</p>
        <fig id="pone-0031196-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Flow cytometry histogram showing binding competition between the labeled and unlabeled SL<sub>2</sub>-B aptamer in HT-29 cells and quantitative analysis of flow cytometry result.</title>
            <p>Red – 0 nM (negative control), green – aptamer binding without excess of unlabeled SL<sub>2</sub>-B aptamer (0.5 nM); pink – aptamer binding in excess of unlabeled SL<sub>2</sub>-B aptamer (unlabeled aptamer – 10 nM, labeled aptamer – 0.5 nM). *Significant difference from the negative control sample at p-value&lt;0.05; **Significant difference from the negative control sample at p-value&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g007" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title><italic>In vitro</italic> fluorescence imaging of SL<sub>2</sub>-B aptamer-VEGF complex</title>
        <p>The targeting ability and specificity of the high affinity SL<sub>2</sub>-B aptamer was further investigated and imaged using live colorectal cancer HT-29 cells and normal MRC-5 fibroblast cells (control) at the same hypoxia conditions. By comparing the bright field and the fluorescent images, we observed red fluorescence on HT-29 cells after exposing to PE-texas red labeled SL<sub>2</sub>-B aptamer (<xref ref-type="fig" rid="pone-0031196-g008">Figure 8A &amp; B</xref>), but no detectable fluorescence was observed with PE-texas red labeled scrambled sequence (<xref ref-type="fig" rid="pone-0031196-g008">Figure 8C &amp; D</xref>). This confirms the specific binding of SL<sub>2</sub>-B aptamer to VEGF<sub>165</sub> protein in cancer cells. For MRC-5 fibroblasts, minimal fluorescence was also observed after exposing to the same SL<sub>2</sub>-B aptamer (<xref ref-type="fig" rid="pone-0031196-g008">Figure 8E &amp; F</xref>). This further demonstrates the specificity and targeting ability of the SL<sub>2</sub>-B aptamer to cancer cells.</p>
        <fig id="pone-0031196-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0031196.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>Binding of PE-texas red-labeled aptamers (SL<sub>2</sub>-B and scrambled sequence) to HT-29 cells and normal MRC-5 fibroblast cells under hypoxia condition.</title>
            <p>(A) &amp; (C) Bright field images of HT-29 cells after exposing to the SL<sub>2</sub>-B and scrambled sequence respectively. (B) &amp; (D) Corresponding fluorescence microscopy images of the (A) &amp; (C) bright field images. (E) &amp; (F) Bright field and fluorescence microscopy images of MRC-5 cells after exposing to the SL<sub>2</sub>-B sequence.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0031196.g008" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>Conclusions</title>
        <p>To summarize, this work attempted to identify in the key binding aptamer sequences by truncating based on the stem-loop structure of the original VEa5 aptamer. From the results, we can conclude that the SL<sub>2</sub> sequence is important for the binding to HBD of the VEGF<sub>165</sub> protein, and the SL<sub>2</sub>-B aptamer binds HBD of VEGF<sub>165</sub> protein strongly and selectively. This newly obtained SL<sub>2</sub>-B aptamer sequence can potentially be useful in oligomer-based cancer therapeutic and diagnostic applications, though further studies are required for better understanding of the SL<sub>2</sub>-B aptamer sequence and to elucidate its binding mechanism with HBD of VEGF<sub>165</sub> protein. Furthermore, the current stem-loop modification approaches can be useful in identifying target domains, getting rid of excessive unnecessary nucleotides, and eventually lowering the cost of aptamer synthesis.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Dr Partha Roy (Division of Bioengineering, National University of Singapore) for providing the HT-29 colorectal cancer cells. We also appreciated the doctoral scholarship (for H.K.) from NUS.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0031196-Bock1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bock</surname><given-names>LC</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>LC</given-names></name><name name-style="western"><surname>Latham</surname><given-names>JA</given-names></name><name name-style="western"><surname>Vermaas</surname><given-names>EH</given-names></name><name name-style="western"><surname>Toole</surname><given-names>JJ</given-names></name></person-group>             <year>1992</year>             <article-title>Selection of single-stranded DNA molecules that bind and inhibit human thrombin.</article-title>             <source>Nature</source>             <volume>355</volume>             <fpage>564</fpage>             <lpage>566</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Wrzesinski1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wrzesinski</surname><given-names>J</given-names></name><name name-style="western"><surname>Ciesiolka</surname><given-names>J</given-names></name></person-group>             <year>2005</year>             <article-title>Characterization of structure and metal ions specificity of Co<sup>2+</sup>-binding RNA aptamers.</article-title>             <source>Biochemistry</source>             <volume>44</volume>             <fpage>6257</fpage>             <lpage>6268</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Davis1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>JH</given-names></name><name name-style="western"><surname>Szostak</surname><given-names>JW</given-names></name></person-group>             <year>2002</year>             <article-title>Isolation of high-affinity GTP aptamers from partially structured RNA libraries.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>99</volume>             <fpage>11616</fpage>             <lpage>11621</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Jayasena1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jayasena</surname><given-names>SD</given-names></name></person-group>             <year>1999</year>             <article-title>Aptamers: An emerging class of molecules that rival antibodies in diagnostics.</article-title>             <source>Clin Chem</source>             <volume>45</volume>             <fpage>1628</fpage>             <lpage>1650</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Ruckman1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ruckman</surname><given-names>J</given-names></name><name name-style="western"><surname>Green</surname><given-names>LS</given-names></name><name name-style="western"><surname>Beeson</surname><given-names>J</given-names></name><name name-style="western"><surname>Waugh</surname><given-names>S</given-names></name><name name-style="western"><surname>Gillette</surname><given-names>WL</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain.</article-title>             <source>J Biol Chem</source>             <volume>273</volume>             <fpage>20556</fpage>             <lpage>20567</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Sayyed1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sayyed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Hägele</surname><given-names>H</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>OP</given-names></name><name name-style="western"><surname>Endlich</surname><given-names>K</given-names></name><name name-style="western"><surname>Segerer</surname><given-names>S</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.</article-title>             <source>Diabetologia</source>             <volume>52</volume>             <fpage>2445</fpage>             <lpage>2454</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Ninichuk1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ninichuk</surname><given-names>V</given-names></name><name name-style="western"><surname>Clauss</surname><given-names>S</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>O</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>H</given-names></name><name name-style="western"><surname>Segerer</surname><given-names>S</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′-PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.</article-title>             <source>Am J Pathol</source>             <volume>172</volume>             <fpage>628</fpage>             <lpage>637</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Bates1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Laber</surname><given-names>DA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DM</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SD</given-names></name><name name-style="western"><surname>Trent</surname><given-names>JO</given-names></name></person-group>             <year>2009</year>             <article-title>Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.</article-title>             <source>Exp Mol Pathol</source>             <volume>86</volume>             <fpage>151</fpage>             <lpage>164</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Waters1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Waters</surname><given-names>EK</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>J</given-names></name><name name-style="western"><surname>Schaub</surname><given-names>RG</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>JC</given-names></name></person-group>             <year>2009</year>             <article-title>Effect of NU172 and bivalirudin on ecarin clotting time in human plasma and whole blood.</article-title>             <source>J Thromb Haemost</source>             <volume>7</volume>             <fpage>683</fpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Diener1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Diener</surname><given-names>JL</given-names></name><name name-style="western"><surname>Daniel Lagassé</surname><given-names>HA</given-names></name><name name-style="western"><surname>Duerschmied</surname><given-names>D</given-names></name><name name-style="western"><surname>Merhi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanguay</surname><given-names>JF</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.</article-title>             <source>J Thromb Haemost</source>             <volume>7</volume>             <fpage>1155</fpage>             <lpage>1162</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Chan1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>MY</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>MG</given-names></name><name name-style="western"><surname>Dyke</surname><given-names>CK</given-names></name><name name-style="western"><surname>Myles</surname><given-names>SK</given-names></name><name name-style="western"><surname>Aberle</surname><given-names>LG</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.</article-title>             <source>Circulation</source>             <volume>117</volume>             <fpage>2865</fpage>             <lpage>2874</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Biesecker1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Biesecker</surname><given-names>G</given-names></name><name name-style="western"><surname>Dihel</surname><given-names>L</given-names></name><name name-style="western"><surname>Enney</surname><given-names>K</given-names></name><name name-style="western"><surname>Bendele</surname><given-names>RA</given-names></name></person-group>             <year>1999</year>             <article-title>Derivation of RNA aptamer inhibitors of human complement C5.</article-title>             <source>Immunopharmacology</source>             <volume>42</volume>             <fpage>219</fpage>             <lpage>230</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Green1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>LS</given-names></name><name name-style="western"><surname>Jellinek</surname><given-names>D</given-names></name><name name-style="western"><surname>Jenison</surname><given-names>R</given-names></name><name name-style="western"><surname>Ostman</surname><given-names>A</given-names></name><name name-style="western"><surname>Heldin</surname><given-names>CH</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Inhibitory DNA ligands to platelet-derived growth factor B-chain.</article-title>             <source>Biochemistry</source>             <volume>35</volume>             <fpage>14413</fpage>             <lpage>14424</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Ellington1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ellington</surname><given-names>AD</given-names></name><name name-style="western"><surname>Szostak</surname><given-names>JW</given-names></name></person-group>             <year>1990</year>             <article-title>In vitro selection of RNA molecules that bind specific ligands.</article-title>             <source>Nature</source>             <volume>346</volume>             <fpage>818</fpage>             <lpage>822</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Tuerk1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tuerk</surname><given-names>C</given-names></name><name name-style="western"><surname>Gold</surname><given-names>L</given-names></name></person-group>             <year>1990</year>             <article-title>Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.</article-title>             <source>Science</source>             <volume>249</volume>             <fpage>505</fpage>             <lpage>510</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Misono1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Misono</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>PKR</given-names></name></person-group>             <year>2005</year>             <article-title>Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance.</article-title>             <source>Anal Biochem</source>             <volume>342</volume>             <fpage>312</fpage>             <lpage>317</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Berezovski1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Berezovski</surname><given-names>M</given-names></name><name name-style="western"><surname>Drabovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Krylova</surname><given-names>SM</given-names></name><name name-style="western"><surname>Musheev</surname><given-names>M</given-names></name><name name-style="western"><surname>Okhonin</surname><given-names>V</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Nonequilibrium capillary electrophoresis of equilibrium mixtures: A universal tool for development of aptamers.</article-title>             <source>J Am Chem Soc</source>             <volume>127</volume>             <fpage>3165</fpage>             <lpage>3171</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Tok1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tok</surname><given-names>JB</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>NO</given-names></name></person-group>             <year>2008</year>             <article-title>Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin.</article-title>             <source>Chem Comm</source>             <fpage>1883</fpage>             <lpage>1885</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Jellinek1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jellinek</surname><given-names>D</given-names></name><name name-style="western"><surname>Green</surname><given-names>LS</given-names></name><name name-style="western"><surname>Bell</surname><given-names>C</given-names></name><name name-style="western"><surname>Lynott</surname><given-names>CK</given-names></name><name name-style="western"><surname>Gill</surname><given-names>N</given-names></name><etal/></person-group>             <year>1995</year>             <article-title>Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.</article-title>             <source>Biochemistry</source>             <volume>34</volume>             <fpage>11363</fpage>             <lpage>11372</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Pagratis1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pagratis</surname><given-names>NC</given-names></name><name name-style="western"><surname>Bell</surname><given-names>C</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YF</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>S</given-names></name><name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor.</article-title>             <source>Nature Biotechnol</source>             <volume>15</volume>             <fpage>68</fpage>             <lpage>73</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Chelliserrykattil1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chelliserrykattil</surname><given-names>J</given-names></name><name name-style="western"><surname>Ellington</surname><given-names>AD</given-names></name></person-group>             <year>2004</year>             <article-title>Evolution of a T7 RNA polymerase variant that transcribes 2′-<italic>O</italic>-methyl RNA.</article-title>             <source>Nature Biotechnol</source>             <volume>22</volume>             <fpage>1155</fpage>             <lpage>1160</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Hernandez1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Kalra</surname><given-names>N</given-names></name><name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name><name name-style="western"><surname>Vester</surname><given-names>B</given-names></name></person-group>             <year>2009</year>             <article-title>Aptamers as a model for functional evaluation of LNA and 2′-amino LNA.</article-title>             <source>Bioorg Med Chem Lett</source>             <volume>19</volume>             <fpage>6585</fpage>             <lpage>6587</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Schmidt1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>KS</given-names></name><name name-style="western"><surname>Borkowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Kurreck</surname><given-names>J</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>AW</given-names></name><name name-style="western"><surname>Bald</surname><given-names>R</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.</article-title>             <source>Nucleic Acids Res</source>             <volume>32</volume>             <fpage>5757</fpage>             <lpage>5765</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Kawasaki1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>AM</given-names></name><name name-style="western"><surname>Casper</surname><given-names>MD</given-names></name><name name-style="western"><surname>Freier</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lesnik</surname><given-names>EA</given-names></name><name name-style="western"><surname>Zounes</surname><given-names>MC</given-names></name><etal/></person-group>             <year>1993</year>             <article-title>Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.</article-title>             <source>J Med Chem</source>             <volume>36</volume>             <fpage>831</fpage>             <lpage>841</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Somasunderam1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Somasunderam</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>DR</given-names></name><name name-style="western"><surname>Thiviyanathan</surname><given-names>V</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase.</article-title>             <source>Biochemistry</source>             <volume>44</volume>             <fpage>10388</fpage>             <lpage>10395</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Boomer1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Boomer</surname><given-names>RM</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>SD</given-names></name><name name-style="western"><surname>Healy</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues.</article-title>             <source>Oligonucleotides</source>             <volume>15</volume>             <fpage>183</fpage>             <lpage>195</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Kato1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Yano</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikebukuro</surname><given-names>K</given-names></name><name name-style="western"><surname>Karube</surname><given-names>I</given-names></name></person-group>             <year>2000</year>             <article-title>Interaction of three-way DNA junctions with steroids.</article-title>             <source>Nucleic Acids Res</source>             <volume>28</volume>             <fpage>1963</fpage>             <lpage>1968</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Shangguan1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shangguan</surname><given-names>D</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mallikaratchy</surname><given-names>P</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group>             <year>2007</year>             <article-title>Optimization and modifications of aptamers selected from live cancer cell lines.</article-title>             <source>ChemBioChem</source>             <volume>8</volume>             <fpage>603</fpage>             <lpage>606</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Sayer1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sayer</surname><given-names>NM</given-names></name><name name-style="western"><surname>Cubin</surname><given-names>M</given-names></name><name name-style="western"><surname>Rhie</surname><given-names>A</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>M</given-names></name><name name-style="western"><surname>Tahiri-Alaoui</surname><given-names>A</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Structural determinants of conformationally selective, prion-binding aptamers.</article-title>             <source>J Biol Chem</source>             <volume>279</volume>             <fpage>13102</fpage>             <lpage>13109</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Katilius1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Katilius</surname><given-names>E</given-names></name><name name-style="western"><surname>Flores</surname><given-names>C</given-names></name><name name-style="western"><surname>Woodbury</surname><given-names>NW</given-names></name></person-group>             <year>2007</year>             <article-title>Exploring the sequence space of a DNA aptamer using microarrays.</article-title>             <source>Nucleic Acids Res</source>             <volume>35</volume>             <fpage>7626</fpage>             <lpage>7635</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Houck1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Houck</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name><name name-style="western"><surname>Winer</surname><given-names>J</given-names></name><name name-style="western"><surname>Cachianes</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><etal/></person-group>             <year>1991</year>             <article-title>The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA.</article-title>             <source>Mol Endocrinol</source>             <volume>5</volume>             <fpage>1806</fpage>             <lpage>1814</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Park1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name><name name-style="western"><surname>Keller</surname><given-names>GA</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name></person-group>             <year>1993</year>             <article-title>The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.</article-title>             <source>Mol Biol Cell</source>             <volume>4</volume>             <fpage>1317</fpage>             <lpage>1326</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Cohen1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>T</given-names></name><name name-style="western"><surname>Gitay-Goren</surname><given-names>H</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>R</given-names></name><name name-style="western"><surname>Shibuya</surname><given-names>M</given-names></name><name name-style="western"><surname>Halaban</surname><given-names>R</given-names></name><etal/></person-group>             <year>1995</year>             <article-title>VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.</article-title>             <source>J Biol Chem</source>             <volume>270</volume>             <fpage>11322</fpage>             <lpage>11326</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Keyt1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Keyt</surname><given-names>BA</given-names></name><name name-style="western"><surname>Berleau</surname><given-names>LT</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HV</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Heinsohn</surname><given-names>H</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency.</article-title>             <source>J Biol Chem</source>             <volume>271</volume>             <fpage>7788</fpage>             <lpage>7795</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Hasegawa1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Sode</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikebukuro</surname><given-names>K</given-names></name></person-group>             <year>2008</year>             <article-title>Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method.</article-title>             <source>Biotechnol Lett</source>             <volume>30</volume>             <fpage>829</fpage>             <lpage>834</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Hasegawa2">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Taira</surname><given-names>KI</given-names></name><name name-style="western"><surname>Sode</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikebukuro</surname><given-names>K</given-names></name></person-group>             <year>2008</year>             <article-title>Improvement of aptamer affinity by dimerization.</article-title>             <source>Sensors</source>             <volume>8</volume>             <fpage>1090</fpage>             <lpage>1098</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Zuker1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zuker</surname><given-names>M</given-names></name></person-group>             <year>2003</year>             <article-title>Mfold web server for nucleic acid folding and hybridization prediction.</article-title>             <source>Nucleic Acids Res</source>             <volume>31</volume>             <fpage>3406</fpage>             <lpage>3415</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Potty1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Potty</surname><given-names>ASR</given-names></name><name name-style="western"><surname>Kourentzi</surname><given-names>K</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>GW</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Biophysical characterization of DNA aptamer interactions with vascular endothelial growth factor.</article-title>             <source>Biopolymers</source>             <volume>91</volume>             <fpage>145</fpage>             <lpage>156</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Davis2">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>B</given-names></name><name name-style="western"><surname>Jayasena</surname><given-names>SD</given-names></name></person-group>             <year>1998</year>             <article-title>Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry.</article-title>             <source>Nucleic Acids Res</source>             <volume>26</volume>             <fpage>3915</fpage>             <lpage>3924</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Daniels1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>DA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Hicke</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Swiderek</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gold</surname><given-names>L</given-names></name></person-group>             <year>2003</year>             <article-title>A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>100</volume>             <fpage>15416</fpage>             <lpage>15421</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Waleh1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Waleh</surname><given-names>NS</given-names></name><name name-style="western"><surname>Brody</surname><given-names>MD</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mendonca</surname><given-names>HL</given-names></name><name name-style="western"><surname>Lord</surname><given-names>EM</given-names></name><etal/></person-group>             <year>1995</year>             <article-title>Mapping of the vascular endothelial growth factor-producing hypoxie cells in multicellular tumor spheroids using a hypoxia-specific marker.</article-title>             <source>Cancer Res</source>             <volume>55</volume>             <fpage>6222</fpage>             <lpage>6226</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Oswald1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Oswald</surname><given-names>J</given-names></name><name name-style="western"><surname>Treite</surname><given-names>F</given-names></name><name name-style="western"><surname>Haase</surname><given-names>C</given-names></name><name name-style="western"><surname>Kampfrath</surname><given-names>T</given-names></name><name name-style="western"><surname>Mäding</surname><given-names>P</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Experimental hypoxia is a potent stimulus for radiotracer uptake <italic>in vitro</italic>: Comparison of different tumor cells and primary endothelial cells.</article-title>             <source>Cancer Lett</source>             <volume>254</volume>             <fpage>102</fpage>             <lpage>110</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Calvani1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Calvani</surname><given-names>M</given-names></name><name name-style="western"><surname>Trisciuoglio</surname><given-names>D</given-names></name><name name-style="western"><surname>Bergamaschi</surname><given-names>C</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>RH</given-names></name><name name-style="western"><surname>Melillo</surname><given-names>G</given-names></name></person-group>             <year>2008</year>             <article-title>Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.</article-title>             <source>Cancer Res</source>             <volume>68</volume>             <fpage>285</fpage>             <lpage>291</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Vaupel1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vaupel</surname><given-names>P</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>A</given-names></name></person-group>             <year>2007</year>             <article-title>Hypoxia in cancer: Significance and impact on clinical outcome.</article-title>             <source>Cancer Metast Rev</source>             <volume>26</volume>             <fpage>225</fpage>             <lpage>239</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Minchenko1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Minchenko</surname><given-names>A</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T</given-names></name><name name-style="western"><surname>Salceda</surname><given-names>S</given-names></name><name name-style="western"><surname>Caro</surname><given-names>J</given-names></name></person-group>             <year>1994</year>             <article-title>Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo.</article-title>             <source>Lab Invest</source>             <volume>71</volume>             <fpage>374</fpage>             <lpage>379</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Neufeld1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Neufeld</surname><given-names>G</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>T</given-names></name><name name-style="western"><surname>Gengrinovitch</surname><given-names>S</given-names></name><name name-style="western"><surname>Poltorak</surname><given-names>Z</given-names></name></person-group>             <year>1999</year>             <article-title>Vascular endothelial growth factor (VEGF) and its receptors.</article-title>             <source>FASEB J</source>             <volume>13</volume>             <fpage>9</fpage>             <lpage>22</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Ikeda1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>E</given-names></name><name name-style="western"><surname>Achen</surname><given-names>MG</given-names></name><name name-style="western"><surname>Breier</surname><given-names>G</given-names></name><name name-style="western"><surname>Risau</surname><given-names>W</given-names></name></person-group>             <year>1995</year>             <article-title>Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.</article-title>             <source>J Biol Chem</source>             <volume>270</volume>             <fpage>19761</fpage>             <lpage>19766</lpage>          </element-citation>
      </ref>
      <ref id="pone.0031196-Shima1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shima</surname><given-names>DT</given-names></name><name name-style="western"><surname>Deutsch</surname><given-names>U</given-names></name><name name-style="western"><surname>D'Amore</surname><given-names>PA</given-names></name></person-group>             <year>1995</year>             <article-title>Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability.</article-title>             <source>FEBS Lett</source>             <volume>370</volume>             <fpage>203</fpage>             <lpage>208</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>